Skip to main content

Advertisement

SpringerLink
Log in

MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF

  • Research Article
  • Published:
Tumor Biology

Abstract

MicroRNAs (miRNAs) play critical roles in the development and progression of ovarian cancer. We found that miR-212 was significantly downregulated in serum and tissues from epithelial ovarian cancer (EOC) patients. Overexpression of miR-212 in ovarian cancer cells inhibited cell proliferation, migration, and invasion. Luciferase reporter assay confirmed HBEGF as a direct target of miR-212. Overexpression of miR-212 decreased HBEGF expression at both the protein and messenger RNA (mRNA) levels. Knockdown of HBEGF expression in SKOV3 cell line significantly inhibited cell growth, migration, and invasion. HBEGF mRNA level was upregulated in EOC tissues and inversely correlated with miR-212 expression in tissues. Upregulation of HBEGF could attenuate the effect induced by miR-212. These findings indicate that miR-212 displays a tumor-suppressive effect in human ovarian cancer. And miR-212 suppresses cell proliferation, migration, and invasion by targeting the HBEGF transcript, highlighting the therapeutic potential of miR-212 and HBEGF in epithelial ovarian cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Google Scholar 

  2. Marcus CS, Maxwell GL, Darcy KM, et al. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer. 2014;5(1):25–30.

    Article  Google Scholar 

  3. Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011;3:83–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Xi JJ. MicroRNAs in cancer. Cancer Treat Res. 2013;158:119–37.

    Article  Google Scholar 

  5. Liang X, Zeng J, Wang L, Fang M, Wang Q, Zhao M, et al. Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212. PLoS ONE. 2013;8:e69784.

    Article  CAS  Google Scholar 

  6. Jiping Z, Ming F, Lixiang W, Xiuming L, Yuqun S, Han Y, et al. MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2. J Cell Biochem. 2013;114:2666–72.

    Article  Google Scholar 

  7. Meng X, Wu J, Pan C, Wang H, Ying X, Zhou Y, et al. Genetic and epigenetic down-regulation of microRNA-212 promotes colorectal tumor metastasis via dysregulation of MnSOD. Gastroenterology. 2013;145(2):426–36.

    Article  CAS  Google Scholar 

  8. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20:207–25.

    Article  CAS  Google Scholar 

  9. Li Y, Zhang D, Chen C, et al. MicroRNA-212 displays tumor-promoting properties in non-small cell lung cancer cells and targets the hedgehog pathway receptor PTCH1. Mol Biol Cell. 2012;23:1423–34.

    Article  CAS  Google Scholar 

  10. Ma C, Nong K, Wu B, et al. miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1. J Exp Clin Cancer Res. 2014;33:54.

    Article  Google Scholar 

  11. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 1991;251:936–9.

    Article  CAS  Google Scholar 

  12. Raab G, Higashiyama S, Hetelekidis S, et al. Biosynthesis and processing by phorbol ester of the cells surface-associated precursor form of heparin-binding EGF-like growth factor. Biochem Biophys Res Commun. 1994;204:592–7.

    Article  CAS  Google Scholar 

  13. Higashiyama S, Lau K, Besner GE, et al. Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem. 1992;267:6205–12.

    Article  CAS  Google Scholar 

  14. Higashiyama S, Abraham JA, Klagsbrun M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol. 1993;122:933–40.

    Article  CAS  Google Scholar 

  15. Marikovsky M, Breuing K, Liu PY, et al. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci U S A. 1993;90:3889–93.

    Article  CAS  Google Scholar 

  16. Hashimoto K, Higashiyama S, Asada H, et al. Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem. 1994;269:20060–6.

    Article  CAS  Google Scholar 

  17. Peoples GE, Blotnick S, Takahashi K, et al. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci U S A. 1995;92:6547–51.

    Article  CAS  Google Scholar 

  18. Higashiyama S, Iwamoto R, Goishi K, et al. The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol. 1995;128:929–38.

    Article  CAS  Google Scholar 

  19. Iwamoto R, Higashiyama S, Mitamura T, et al. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J. 1994;13:2322–30.

    Article  CAS  Google Scholar 

  20. Yotsumoto F, Yagi H, Suzuki SO, et al. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun. 2008;365(3):555–61.

    Article  CAS  Google Scholar 

  21. Miyamoto S, Hirata M, Yamazaki A, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res. 2004;64:5720–7.

    Article  CAS  Google Scholar 

  22. Ohnishi Y, Inoue H, Furukawa M, et al. Heparin-binding epidermal growth factor-like growth factor is a potent regulator of invasion activity in oral squamous cell carcinoma. Oncol Rep. 2012;27:954–8.

    Article  CAS  Google Scholar 

  23. Haugen DR, Akslen LA, Varhaug JE, et al. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res. 1996;56:1184–8.

    CAS  PubMed  Google Scholar 

  24. Chandler LA, Sosnowski BA, McDonald JR, et al. Targeting tumor cells via EGF receptors: selective toxicity of an HBEGF-toxin fusion protein. Int J Cancer. 1998;78:106–11.

    Article  CAS  Google Scholar 

  25. Ota I, Higashiyama S, Masui T, et al. Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells. Oncol Rep. 2013;30:1593–600.

    Article  CAS  Google Scholar 

  26. Zhou Z N, Sharma V P, Beaty B T, et al. Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo. Oncogene, 2013.

Download references

Conflicts of interest

None

Acknowledgments

This work was supported by the Education department of Henan province science and technology research projects (12A320035). We thank Yan-mei Ma for generally providing the SKOV3 cell line.

Author information

Authors and Affiliations

  1. Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe Road, Zhengzhou, 450052, Henan, China

    Li-qiang Wei, Dong-chun Qin, Hui-fang Jin, Yong Zhao & Ming-cong She

  2. Red Cross Blood Center of He’nan Province, Zhengzhou, 450052, Henan, China

    Hui-tao Liang

Authors
  1. Li-qiang Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui-tao Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong-chun Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui-fang Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ming-cong She
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong-chun Qin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wei, Lq., Liang, Ht., Qin, Dc. et al. MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF. Tumor Biol. 35, 12427–12434 (2014). https://doi.org/10.1007/s13277-014-2560-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2560-2

Keywords

Search

Navigation